Melanoma treatment: Potential target bypasses therapeutic resistance to immune checkpoint blockers: The clinically approved drug ruxolitinib suppressed a mouse model of melanoma that is resistant to immune checkpoint blockers.

Over the last decade, immune checkpoint blockers, or ICBs, have revolutionized treatment for various advanced cancers, including melanoma, the most aggressive skin cancer that was considered largely incurable not long ago. However, three-fourths of advanced-melanoma patients are resistant to ICBs. Now, researchers reveal a potential target — using the clinically approved drug ruxolitinib — to suppress ICB-resistant melanomas.

Leave a Comment